ABSTRACT
Panama is the first country in the Central American region that has officially discarded chloroquine as a first-line drug to treat Plasmodium falciparum cases. Here we describe the clinical and molecular findings from autochthonous P. falciparum fatal cases, and the epidemiological situation that led to a change in the national antimalarial drug policy. Our results illustrate the potential pathogenicity of the strain of P. falciparum circulating in the country and provide molecular evidence of parasite resistance to chloroquine and antifolate drugs. The public health threats of these findings for the Central American region are discussed.
Subject(s)
Antimalarials/therapeutic use , Chloroquine/therapeutic use , Drug Resistance/genetics , Malaria, Falciparum/drug therapy , Plasmodium falciparum/drug effects , Adult , Animals , Child, Preschool , DNA, Protozoan/analysis , Fatal Outcome , Female , Genotype , Health Policy/legislation & jurisprudence , Humans , Male , Mutation/genetics , Panama , Plasmodium falciparum/genetics , PregnancyABSTRACT
An outbreak of hantavirus pulmonary syndrome occurred in the province of Los Santos, Panama, in late 1999 and early 2000. Eleven cases were identified; 9 were confirmed by serology. Three cases were fatal; however, no confirmed case-patient died. Case-neighborhood serologic surveys resulted in an overall hantavirus antibody prevalence of 13% among household and neighborhood members from the outbreak foci. Epidemiologic investigations did not suggest person-to-person transmission of hantavirus infection. By use of Sin Nombre virus antigen, hantavirus antibodies were detected in Oligoryzomys fulvescens and Zygodontomys brevicauda cherriei. This outbreak resulted in the first documented cases of human hantavirus infections in Central America.